Hjem › Fenylketonuri › Texas
Fenylketonuri kliniske forsøg i Texas
7 studier for Fenylketonuri søger deltagere på steder i Texas.
Byer i Texas
Officiel studietekst (engelsk)
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
- University of Texas Southwestern Medical Center (UTSW), Dallas
RekruttererFase 1
Alder 18 til 69 · Alle køn · Opdateret 28. sep. 2026 · NCT07241234AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)
- University or Texas, Southwestern medical Center, Dallas
RekruttererFase 1/2
Alder 18 til 55 · Alle køn · Opdateret 18. aug. 2026 · NCT06332807A Study of JNT-517 in Participants With Phenylketonuria (PKU)
- University of Texas Southwestern, Dallas
- University of Texas Health (UTHealth) Science Center at Houston, Houston
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 8. jul. 2026 · NCT06971731Immune Modulation During Palynziq® Treatment in Adults (IMPALA)
- UT Southwestern Medical Center, Dallas
RekruttererFase 4
Alder 18 til 65 · Alle køn · Opdateret 17. jun. 2026 · NCT07477691A Long-Term Study of JNT-517 in Participants With Phenylketonuria
- Children's Medical Center Dallas, Dallas
- University of Texas Southwestern Medical Center, Dallas
- University of Texas Health (UTHealth) Science Center at Houston, Houston
RekruttererFase 3
Alder 4 og opefter · Alle køn · Opdateret 1. maj 2026 · NCT06628128A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
- University of Texas Southwestern Medical Center, Dallas
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 25. mar. 2026 · NCT05813678A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
- UT Southwestern Medical Center, Dallas
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 24. mar. 2026 · NCT06305234Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.